微信内可能无法直接打开本站。请点右上角 ··· → 在浏览器打开，或复制链接。
STAT+: Novartis’ experimental cardiovascular drug fails a pivotal study
RSS 官方收录 · 可信分层展示
关键摘要
A closely watched cardiovascular drug from Novartis failed in a pivotal study, the company said Friday, a major blow to the firm and to efforts to target a common heart disease risk factor.…
- The drug, called pelacarsen, had shown in earlier trials that it could…
- But Novartis said that in the Phase 3 HORIZON trial, pelacarsen failed…
- Continue to STAT+ to read the full story…
摘要引擎：抽取
正文提要
A closely watched cardiovascular drug from Novartis failed in a pivotal study, the company said Friday, a major blow to the firm and to efforts to target a common heart disease risk factor.
The drug, called pelacarsen, had shown in earlier trials that it could drastically lower levels of what’s called Lp(a), a little blob of lipids and proteins that at elevated concentrations increases the likelihood of severe heart problems.
But Novartis said that in the Phase 3 HORIZON trial, pelacarsen failed to reduce the risk of cardiovascular death or emergencies like heart attacks or stroke compared to placebo.